



SCIENTIFIC PROGRAM

ALL PRESENTATIONS AT THE ANNUAL SCIENTIFIC MEETING ARE THE OPINIONS AND RESEARCH OF THE PRESENTERS AND AUTHORS FOR THE PURPOSES OF DEBATE AND REFLECTION. THEY ARE NOT THE VIEWS OR POLICIES OF COLLEGE

SATURDAY 18 MAY 2019

0700-1800 REGISTRATION DESK OPEN

0830-0845 ASM OPENING
Room: Goldfields Theatre

0830-0845 **Dr A. Miller**
President's welcome

0845-1015 MEDICAL DERMATOLOGY
Room: Goldfields Theatre
Chairs: Dr M. Mohamed, A/Prof. R. Nixon, Dr A. Yazdabadl

0845-0910 **Prof. J. Bolognia**
Lessons from a practising dermatologist

0910-0935 **Prof. E. Schmidt**
Current and emerging treatments for immunobullous disease

0935-1000 **Dr J. McFadden**
The detective's guide to contact dermatitis

1000-1005 Q & A

1005-1015 **Prof. H. P. Soyer**
Australian Centre of Excellence for Melanoma Imaging and Diagnosis

1015 END OF SESSION

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALLS 23-25

1100-1230 PERSPECTIVES FROM MELBOURNE
Room: Goldfields Theatre
Chairs: Dr B. Daniel, Dr M. Goh

1100-1110 Dr M. Goh
Toxic epidermal necrolysis (TEN) update

1110-1125 Prof. M. Leech
The future of medical education

1125-1140 Prof. M. Leech
Rheumatology update

1140-1200 Dr G. Rennick
(My) Favourite mnemonics

1200-1215 Dr M. Webster
Ray, ray, go away: radiotherapy update

1215-1230 Q & A

1230 END OF SESSION

1230-1345 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1345-1545 CLINICOPATHOLOGICAL CORRELATION
Room: Goldfields Theatre
Chairs: Dr M. Mohamed, Dr A. Wright

1345-1545 Presented by Victorian dermatologists, pathologists and trainees
Clinicopathological correlation: Cases with interesting clinical and histological features

1545 END OF SESSION

1345-1530 MOHS'
Room: Eureka Meeting Room 1

1345-1400 Dr A. Wu
Management of sebaceous carcinoma

1400-1430 A/Prof. C. Baker and Dr M. Guiney
VMAT XRT

1430-1440 Dr H. Smith
A meta analysis of mohs infection rates

1440-1500 Dr A. Verma
New regulations in Victoria

1500-1510 Dr E. Upjohn
Mohs for melanoma redux

1510-1520 Dr A. Quinn
Alar defects repaired with island pedicle flaps

1520-1530 Dr H. Smith
A retrospective database analysis of risk factors for mohs infection

1530 END OF SESSION

1545-1615 AFTERNOON TEA IN THE TRADE EXHIBITION, HALLS 23-25

NOW PBS LISTED¹

IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

**SUPERIOR SKIN CLEARANCE
SHOULD STAND
THE TEST OF TIME^{2-4†}**

[†]More patients achieved PASI 90 at Week 16 (73.3% vs 49.7%; $p < 0.001$) and Week 48 (76.3% vs 47.9%; $p < 0.001$) vs adalimumab²⁻⁴

 **Tremfya[®]**
(guselkumab)

PBS Information: Authority Required. Refer to PBS Schedule for full authority information.

Please review Product Information before prescribing (available from http://www.janssen.com.au/Tremfya_PI)

TREMFYA[®] (guselkumab) MINIMUM PRODUCT INFORMATION. INDICATIONS: TREMFYA is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS: Serious hypersensitivity to guselkumab or any of the excipients. PRECAUTIONS: Infections: TREMFYA may increase risk of infections. Tuberculosis (TB): Evaluate for TB prior to initiating treatment. Do not administer to patients with active TB. Treat latent TB before administration. Consider anti-TB therapy in patients with suspected TB. Monitor patients for TB during and after treatment. *Hypersensitivity reactions: Serious hypersensitivity reactions have been reported in the postmarketing setting. Some cases occurred several days after treatment with guselkumab, including cases with urticaria and dyspnea. Immunisations: Live vaccines should not be used concurrently in patients treated with TREMFYA. Before live viral or live bacterial vaccination, treatment with TREMFYA should be withheld for at least 12 weeks from last dose and not resumed for at least 2 weeks after vaccination. See full PI. Use in Pregnancy – Category B1. INTERACTIONS: Live vaccines. No other meaningful interactions have been identified. see full PI. ADVERSE EFFECTS: Injection site reactions; diarrhoea; upper respiratory infections; gastroenteritis; herpes simplex infections; tinea infections; arthralgia; headache. DOSAGE AND ADMINISTRATION: Subcutaneous injection. 100 mg at week 0, week 4 and every 8 weeks thereafter. PRESENTATION: Pre-filled 1mL glass syringe in a passive needle-guard delivery system. STORAGE CONDITIONS: Store in a refrigerator (2°C – 8°C). Do not freeze. Do not shake. Protect from light. Date of preparation: 11 February 2019.

**Please note changes to Product Information*

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

PASI: Psoriasis Area and Severity Index. References: 1. Australian Government Department of Health. Available at: pbs.gov.au. 2. TREMFYA (guselkumab) Approved Product Information, 8 November 2018. 3. Blauvelt A et al. J Am Acad Dermatol 2017;76:405–17. 4. Griffiths CEM et al. J Drugs Dermatol 2018;17:826–32. ©Janssen-Cilag Pty Ltd 2019. Trademarks and brand names are the property of Johnson & Johnson, its affiliates or third party owners. Janssen-Cilag Pty Ltd, ABN 47 000 129 975. 1-5 Khartoum Road, Macquarie Park NSW 2113. Phone: 1800 226 334. CP-60496. JANS2701/EMBC. Date of preparation: March 2019.

 **Janssen Immunology**
PHARMACEUTICAL COMPANIES OF 

<p>1615-1745 ATOPIC DERMATITIS Room: Goldfields Theatre Chairs: A/Prof. J. Su, Dr J. Ng</p>	<p>1615-1715 MOHS' Room: Eureka Meeting Room 1</p>	<p>1615-1745 REGISTRAR SESSION Room: Eureka Meeting Rooms 2 & 3 Chairs: Dr A. Lee, Dr H. Roberts</p>
<p>1615-1645 Prof. K. Kabashima Genotype correlations and personalised medicine in Atopic Dermatitis</p>	<p>1615-1630 A/Prof. C. Schmults Topic TBC</p>	<p>1615-1620 Dr A. Tatian Patching the unstable atopic gap</p>
<p>1645-1700 A/Prof. A. Lowe AD Epidemiology and prevention</p>	<p>1630-1645 TBC</p>	<p>1620-1625 Dr A. Mulcahy Infantile haemangioma - A small case series involving associated limb overgrowth</p>
<p>1700-1715 Dr J. Ruddle Eye complications of AD and their management</p>	<p>1645-1715 Dr A. Sheridan QAP</p>	<p>1625-1630 Dr E. Forward Diagnostic clues and management principles of childhood psoriasis</p>
<p>1715-1730 A/Prof M Rademaker AD management - case studies</p>	<p>1715 END OF SESSION</p>	<p>1630-1635 Dr E. Forward An overview of vulval Crohn's disease</p>
<p>1730-1745 A/Prof. J. Su Update on topical and systemic therapies</p>		<p>1635-1640 Dr V. Harris Micro-ablative carbon dioxide laser for vulvovaginal atrophy/genitourinary syndrome of menopause</p>
<p>1745 END OF SESSION</p>		<p>1640-1645 Dr H. Bala Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma in an Australian cohort</p>
		<p>1645-1650 Dr G. Farrah The use of omalizumab for treatment - Refractory chronic spontaneous urticaria in a west Australian outpatient cohort</p>
		<p>1650-1655 Dr B. Yau Strongyloides stercoralis detection in patients with dermatological disorders on biologic medication: Preventing hyper-infection and disseminated disease</p>
		<p>1655-1700 Dr P. Dickson How to build an app without making rash decisions</p>
		<p>1700-1705 Dr S. Rea Cost burden analysis of renal transplant patients in tropical far north Queensland</p>
		<p>1705-1710 Dr AJ Sykes Basal cell carcinomas grow slowly and accumulate dermatoscopy features</p>
		<p>1710-1715 Dr S. Thomas Change detection of skin lesions using 3-D total body photography versus conventional dermoscopic images</p>
		<p>1715-1720 Dr M. Tran Changes of melanocytic skin lesions in high-risk individuals and melanoma patients determined by 3D whole body photography and dermoscopy</p>
		<p>1720-1725 Dr M. Hishon Standardised 3-D facial imaging: Exploring the potential for detection of keratinocyte cancer precursor lesions</p>
		<p>1725-1730 Dr R. Yeh Primary wound closure following wide excision of cutaneous melanoma – An evidence based review for clinical practice</p>
		<p>1730-1735 Dr L. Chan The oncological survival and prognosis of individuals receiving PD-1 inhibitor immunologic cutaneous adverse events: A prospective study</p>
		<p>1735-1740 Dr J. Johnston Case of disseminated cryptococcus</p>
		<p>1735-1745 Q & A</p>
		<p>1745 END OF SESSION</p>



1900-2300 COLLEGE PARTY
Room: Melbourne Room 1, MCEC

SATURDAY 18 MAY 2019

SPONSORED BY:  **CANDELA**
Science. Results. Trust.

0730-0830 REGISTRATION AND ARRIVAL TEA AND COFFEE

0830-0845 OPENING SESSION
Room: Goldfields Theatre

0830-0845 Welcome to country
President's welcome, Dr A. Miller

0850-1030 SESSION 1
Room: Sovereign Room

0850-0900 ADNA President welcome and housekeeping
0900-0930 E. Woodhouse
ACN/Dermatology post grad course
0930-1000 Dr R. Saunderson
Informed consent
1000-1030 A. Palmer
Patch testing
1030 END OF SESSION

1030-1100 MORNING TEA IN THE TRADE EXHIBITION, HALLS 23-25

1100-1200 SESSION 2
Room: Sovereign Room

1100-1200 A/Prof. G. Sussman
Wound management
1200 END OF SESSION

1200-1300 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1300-1500 SESSION 3
Room: Sovereign Room

1300-1430 R. Edwards
"It's about you!"
1430-1500 Annual General Meeting
1500 END OF SESSION

1500-1530 AFTERNOON TEA IN THE TRADE EXHIBITION, HALLS 23-25

1530-1645 SESSION 4
Room: Sovereign Room

1530-1600 Dr A. Martin
Advanced dermoscopy and optical coherence tomography of basal cells carcinomas, a volunteer in Nepal
1600-1630 Dr D. Luk
Update on new dermatology wing
1630-1645 E. Polat
Proda-oline biologic applications
1645 END OF SESSION

1830-2300 EGO DINNER, CROWN PROMENADE

SUNDAY 19 MAY 2019

0700-1700 REGISTRATION DESK OPEN

0730-0830	JANSSEN BREAKFAST SYMPOSIUM Room: Meeting Rooms 105 & 106 Chair: Dr D. Rubel	0730-0830	NOVARTIS BREAKFAST SYMPOSIUM Room: Meeting Rooms 109 & 110 Chair: A/Prof P. Foley
0730-0830	Prof. K. Reich and Dr J. Wu Do you see what I see? Personalising treatment plans in Psoriasis	0730-0830	Dr D. Sajic Interesting clinical cases' discussion with an aim of highlighting the comprehensive approach of treating psoriatic disease (more than just a skin disease)
0830	END OF SESSION	0830	END OF SESSION

0845-1015	PAEDIATRIC DERMATOLOGY Room: Goldfields Theatre Chairs: A/Prof. D. Orchard, Dr C. Grills	0845-1015	RECENT SCIENTIFIC ADVANCES IN DERMATOLOGY Room: Eureka Meeting Rooms 2 & 3 Chairs: Prof. G. Varigos, Dr C. Dolianitis, Dr A. Verma	0845-1015	CLIMATE CHANGE AND DERMATOLOGY ROOM: EUREKA Meeting Room 1 Chairs: A/Prof. S. Gilmore, Dr F. Bruce
0845-0905	Prof. P. Vabres Genodermatoses in the neonate	0845-0915	Prof. D. Vaux Research Integrity: the good, the bad, and the ugly	0845-0920	Prof. D. Karoly Climate change and its health implications now and in the future
0905-0918	Dr S. Gibb Managing children with Autism Spectrum Disorder in your office	0915-0935	H. Anderton Cell death, and the microbiome in skin inflammation and disease	0920-0940	Dr F. Bruce Climate change and its impact on infectious and non infectious skin disease
0918-0931	A/Prof. D. Orchard Capillary malformation-Arteriovenous malformation syndrome. An update and management plan	0935-0955	M. Turner, Prof G. A. Varigos, B. Radulski Observational studies and the importance of dermatological registries	0940-0950	A/Prof. S. Gilmore The effects of climate change on skin cancer epidemiology in Australia
0931-0944	Dr M. O'Connell Which children with acne need hormonal investigation?	0955-1015	A/Prof. R. Martyres The emotional health of doctors in Australia: a review, thinking about difficult patients with psychocutaneous disease and managing stress	0950-1005	Dr K. Barraclough Environmental sustainability and healthcare
0944-0957	Ms S. Baird Lessons to be learned from a parent of a child with chronic skin disease			1005-1015	Q & A
0957-1010	Dr S. Choo Cutaneous presentations of immunodeficiency syndromes	1015	END OF SESSION	1015	END OF SESSION
1010-1015	Q & A				
1015	END OF SESSION				

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALLS 23-25

1100-1230	OF ALL THINGS ITCHY, MAST CELL DISORDERS AND MORE Room: Goldfields Theatre Chairs: Dr V. Morgan, Dr J. Rhodes	1100-1230	ACNE AND ROSACEA Room: Eureka Meeting Rooms 2 & 3 Chairs: CL. A/Prof. K. Gebauer, Dr A. Rudd	1100-1230	VASCULAR ANOMALIES Room: Eureka Meeting Room 1 Chairs: A/Prof. L. Scardamaglia, Dr P. Bekhor, Dr S. Robertson
1100-1120	A/Prof. J. Kern Overview, the itchy patient and evidence for the pruritus screen	1100-1130	Dr R. Gallo All about acne	1100-1120	Dr S. Robertson The genetic basis of vascular anomalies
1120-1140	Prof. K. Kabashima Pathogenesis of pruritus	1130-1200	Prof. H. Gollnick Adult acne in females: a problem in the office!	1120-1140	Prof. P. Vabres Novel targeted drug therapy in vascular anomalies and overgrowth syndromes
1140-1200	Dr G. Unglik Mastocytosis	1200-1207	Dr H. Fallah Isotretinoin for acne: An update on adverse effects and monitoring	1140-1155	A/Prof. R. Phillips Beta-blocker therapy for haemangiomas of infancy: recent advances
1200-1220	Dr G. Ross Royal Melbourne Hospital Atopic Dermatitis Clinic- first experience with Dupilumab in severe atopic dermatitis	1207-1230	Q & A	1155-1210	Dr P. Bekhor Laser therapy for vascular anomalies
1220-1230	Q & A	1230	END OF SESSION	1210-1220	A/Prof. L. Scardamaglia Lessons learned from an adult multidisciplinary vascular anomalies clinic
1230	END OF SESSION			s1220-1230	Q & A
				1230	END OF SESSION

1230-1330 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1240-1320 POSTER PRESENTATIONS College Stand Chairs: Dr E. Wee and Dr N. Adler

Dr S. Blake - Omalizumab (xolair) in treatment resistant bullous pemphigoid

Dr B. Doolan - Results from the proof of concept clinical trial – Warfarin for symptomatic therapy in erythropoietic protoporphyria

Dr M. Goldust - Efficacy and safety of a low-level light therapy versus minoxidil 5% solution for treatment of androgenetic alopecia

Dr N. Paththinige - Atypical mycobacterial cutaneous infections - Report of 8 cases from Sri Lanka

Dr K. Phan - mTOR inhibitors and skin cancer risk in non-renal solid organ transplant recipients: Systematic review and meta-analysis

Dr L. Photiou - Tofacitinib for chronic, refractory, moderate to severe alopecia areata. A retrospective review of 127 patients

Dr T. Pitney - Blastocystis hominis associated chronic urticaria rticaria – Report of a case with sucessful response to treatment and review of current literature

Dr M. Zureigat - A case of amicrobial pustulosis of the folds

1330-1500 IMMUNOBULLOUS DISORDERS Room: Goldfields Theatre Chairs: A/Prof. L. Scardamaglia, A/Prof. J. Kern	1330-1500 COSMETIC DERMATOLOGY: CURRENT THINKING AND CONTROVERSIES Room: Eureka Meeting Rooms 2 & 3 Chairs: A/Prof. G. Goodman, Dr L. M. Yap	1330-1500 ETHICS Room: Eureka Meeting Room 1 Chairs: Dr. C. Scarff, Dr E. Ma
1330-1350 Prof. E. Schmidt State of the art diagnosis of immunobullous disease 1350-1355 Q & A 1355-1405 A/Prof. J. Kern Mucous membrane pemphigoid – concepts and controversies 1405-1415 A/Prof. L. Lim Ocular involvement in immunobullous disorders 1415-1425 Dr T. Yap Oral considerations in immunobullous disorders 1425-1430 Q & A 1430-1445 Dr G. Unglik Efficacy and safety of rituximab 1445-1455 A/Prof. L. Scardamaglia Practical use of rituximab for pemphigus vulgaris 1455-1500 Q & A 1500 END OF SESSION	1330-1350 Dr G. Munavalli What's new in lasers 1350-1405 Dr G. Munavalli What's new in non-laser energy based devices 1405-1425 A/Prof. G. Goodman What's new in fillers and deoxycholic acids 1425-1440 Dr D. Lim What's new in acne scarring treatments 1440-1455 A/Prof. M. Freeman What's new in chemical peels and skincare 1455-1500 Q & A 1500 END OF SESSION	1330-1400 Dr R. Srivastava Doctor, how much does it cost? What we mean when we talk about cost 1400-1430 Dr D. Martin The ethics of professionalism-why it matters 1430-1500 Dr A. Chong Anti-vaxxers and flat-earthers: An exploration of science denialism and how we can respond 1500 END OF SESSION

1500-1530 AFTERNOON TEA IN THE TRADE EXHIBITION, HALLS 23-25

1530-1700 LESSONS FROM OTHER SPECIALTIES Room: Goldfields Theatre Chairs: Dr M. Mohamed, Dr L. Ly	1530-1700 PSORIASIS Room: Eureka Meeting Rooms 2 & 3 Chairs: Dr R. Nguyen, Dr J. Sullivan	1530-1700 COSMECEUTICALS Room: Eureka Meeting Room 1 Chairs: Dr B. Welsh, Dr K. Armour
1530-1553 Prof. C. Ng Treatment of OCD-related behaviours and depression in skin disorders 1553-1615 Prof. M. Delatycki Applications of genomics for dermatologists 1615-1638 A/Prof. S. Qureshi Retina: what every dermatologist should know 1638-1700 Prof. P. Johnson Mycobacterium ulcerans: current management 1638-1700 Prof. P. Johnson Mycobacterium ulcerans: current management 1700 END OF SESSION	1530-1540 A/Prof. M. Rademaker and Dr M. Gupta An update on injectable (subcutaneous) methotrexate (Trexjet®): considerations for use in psoriasis (on label PBS) and other inflammatory skin conditions 1540-1545 Dr J. Sullivan Biologic psoriasis therapy 1545-1555 Dr K. Wark and A/Prof. G. Cains Australasian psoriasis registry: our patients on biologic agents and international comparisons 1555-1615 A/Prof. P. Foley, A/Prof. C. Baker and Cl. A/Prof. K. Gebauer Initiating therapy: choosing the right biologic for your patient 1615-1625 Dr D. Rubel Switching biologics in psoriasis: the evidence with practical guidance 1625-1640 Dr M. Gupta and Prof. G. Marshman Flare management: a case study and discussion regarding flare management strategies for psoriasis patients on biologic therapy who experience loss of disease control including rescue, adjunct, combination (and switch) therapy 1640-1650 Dr J. Sullivan and A/Prof. C. Baker Practical Biologic Safety: a case study and discussion of biologic agent safety including class considerations and where safety considerations should influence biologic use and choice 1650-1700 Dr M. Andrews, Dr M. Gupta, Dr M. Rademaker and A/Prof. P. Foley Panel Discussion: are all those investigations really necessary? A case study, my biologic patient work up and monitoring 1700 END OF SESSION	1530-1600 Dr J. McFadden Update on cosmetic allergy 1600-1620 Dr S. Manoharan Cosmeceuticals/topicals for melasma 1620-1640 Dr P. Artemi Antioxidants and peptides 1640-1700 Dr J-A. See Cosmeceuticals in the treatment of rosacea and acne 1640-1700 Dr J-A. See Cosmeceuticals in the treatment of rosacea and acne 1700 END OF SESSION

SUNDAY 19 MAY 2019

0900-1200 SESSION 5
Room: Sovereign Room

- 0900-0930 **C. Peras**
The science and art of photography- a nursing perspective
- 0930-1000 **Dr B. Thompson**
Life of a dermatologist
- 1000-1030 **V. Koslova-Fu**
Specialty and passion in laser therapy
- 1030-1100 **R. Massimo**
The synergy between dermatology and the Dermal clinician
- 1100-1130 **Prof. D. Damian**
Skin cancer prevention for our highest risk patients
- 1130-1200 **M. Funk**
Holding2Hands
- 1200 **END OF SESSION**

1200-1300 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1300-1500 SESSION 6
Room: Sovereign Room

- 1300-1330 **Dr C. Murphy**
Best practice in infection control
- 1330-1400 **Dr B. Mehoranse-Gouveia**
Chronic lymphoma and inflammatory features
- 1400-1430 **Dr S. Blake**
Paediatric dermatology
- 1430-1500 **Award presentations**
- 1500 **END OF SESSION**

GRADUATE FROM THE ACD MOHS MICROGRAPHIC SURGERY TRAINING PROGRAM

Dr Gilberto Moreno Bonilla
Dr Glen Foxton
Dr Shivam Kapila
Dr Adam Quinn
Dr Bonnie Swan
Dr Simon Tucker
Dr Amit Verma

FELLOWS ELECTED UNDER CLAUSE 3.2 OF THE COLLEGE CONSTITUTION

Dr Alexis Lara Rivero

INDUCTION OF NEW FELLOWS

Dr Shreya Andric
Dr Rachael Anforth
Dr Bruno Blaya Alvarez
Dr Lauren Buchanan
Dr Shien-Ning Chee
Dr Andrew Chen
Dr Andrew Freeman
Dr Sarah Gamboni

Dr Alexander Gin
Dr Burcu Kim
Dr Patrick Mahar
Dr Corinne Maiolo
Dr Margit Polcz
Dr Sarah Shen
Dr Alicia Thornton
Dr Shevya Tiwari
Dr Ryan Toholka
Dr Philip Tong
Dr Thevaki Wain
Dr Nerilee Wall
Dr Arabella Walleit
Dr Celestine Wong
Dr Joy Yee

AUSTRALASIAN COLLEGE OF DERMATOLOGISTS TRAVELLING FELLOWSHIP FOR 2018

Dr Shevya Tiwari

FOUNDERS' MEDAL FOR PROCEDURAL DERMATOLOGY FOR 2018

Dr Andrew Chen

KEN PAVER MEDAL FOR MEDICAL DERMATOLOGY FOR 2018

Dr Shevya Tiwari

KOSSARD AWARD FOR DERMATOPATHOLOGY FOR 2018

Dr Lauren Buchanan

Dr Shevya Tiwari

ADRIAN JOHNSON MEMORIAL PRIZE FOR 2018

Dr Margit Marisa Polcz

EILEEN COLLINS MEMORIAL PRIZE FOR 2018

Dr Cathy Zhao

OATH OF ETHICS

The new Fellows will affirm the Oath of Ethics.

The Oath will be recited by Dr Shevya Tiwari.

MUSIC INTERLUDE

Air

JOHN REID ORATION

To be given by Ms Lidia Thorpe

CONCLUSION

The assembly is requested to stand as the academic procession leaves the auditorium.

RECESSIONAL MUSIC

Hornpipe

MUSIC

Music by The Occasional Quartet

Guests of the conferring ceremony are invited to stay and enjoy light refreshments in the Sovereign Room Foyer.



CEREMONY FOR CONFERRING OF FELLOWSHIP AND AWARDS

Sunday 19 May 2019, 6.00pm
Goldfields Theatre
Melbourne Convention and Exhibition Centre
1 Convention Centre Pl
South Wharf VIC 3006

PROGRAM

PROCESSIONAL MUSIC

The Arrival of the Queen of Sheba

ACADEMIC PROCESSION

The audience is requested to stand when the academic procession enters the hall; and to remain standing for the singing of the National Anthems of Australia and New Zealand.

OPENING PROCEEDINGS

Dr Andrew Miller, President of the Australasian College of Dermatologists, will declare the proceedings open and address the assembly

SILVER MEDAL

Dr Ian McCrossin

Associate Professor Orli Wargon OAM

CERTIFICATE OF MERITORIOUS SERVICE

Associate Professor Peter Foley

Dr Anne Halbert

Dr Shawn Richards

Dr Philip Bekhor

Dr Howard Studniberg

HONORARY FELLOW

Dr Paul Salmon

ASSOCIATE MEMBERS

Dr Juliet Burn

Dr Karen Cheung

BELISARIO AWARD FOR ACADEMIC DERMATOLOGY

Professor H. Peter Soyer

INTERNATIONAL OUTREACH AWARD

Associate Professor Gillian Marshman

MERVYN GOLD, OAM, AWARD

Dr Deborah Holt

MONDAY 20 MAY 2019

0700-1700 REGISTRATION DESK OPEN

0730-0830	SANOFI GENZYME BREAKFAST SYMPOSIUM Room: Meeting Rooms 105 & 106 Chair: A/Prof P. Foley	0730-0830	ELI LILLY BREAKFAST SYMPOSIUM Room: Meeting Rooms 109 & 110 Chair: Cl A/Prof S. Smith
0730-0830	Prof. S. Weidinger A new era of atopic dermatitis treatment	0730-0830	Psoriasis and the pursuit of happiness
0830	END OF SESSION	0830	END OF SESSION

0845-1015	SKIN DISORDERS IN THE IMMUNOSUPPRESSED HOST ROOM: GOLDFIELDS THEATRE Chairs: A/Prof. A. Chong, Dr S. Brennand, Dr M. Goh	0845-1015	ADVANCED SURGERY AND SURGERY FOR THE GENERAL DERMATOLOGIST Room: Eureka Meeting Rooms 2 & 3 Chairs: Dr T. Rutherford, Dr E. Upjohn	0845-1015	GENODERMATOSES Room: Eureka Meeting Room 1 Chairs: Prof. I. Winship, Dr S. Robertson
0845-0905	A/Prof. C. Schmults Managing high risk skin cancers in the immunosuppressed patient - the Dana Faber experience	0845-0905	Dr H. Smith What can and cannot prevent a wound infection in your patient evidence from mohs surgery	0845-0915	Prof. I. Winship Genetics and genomics made easy - a clinical illustration of new technology, its application and utility in dermatology
0905-0925	A/Prof. D. Goodman Practical immunosuppression - how to deal with problems in every-day immunosuppression	0905-0920	Dr P. Bekhor Fillers are not just for vain people	0915-0925	Dr S. Robertson Mosaicism in dermatology: an illustrative case report
0925-0945	Dr J. Darby Infective problems in immunosuppressed patients	0920-0940	Dr L. J. Leow MBS update	0925-0945	Prof. P. Vabres Skin mosaicism: clinical clues and genomic advances
0945-1005	A/Prof. A. Chong Lessons from a dedicated transplant dermatology clinic	0940-0950	Dr T. Rutherford Nasofacial and cheek reconstruction	0945-0955	A/Prof. D. Buchanan Sebaceous skin lesions and Lynch Syndrome, a definitive study
1005-1015	Q & A	0950-1000	Dr E. Upjohn Temples and preauricular closures	0955-1015	Q & A
1015	END OF SESSION	1000-1010	Dr E. Tan Ear: helical defects and conchal bowl closures	1015	END OF SESSION
		1010-1015	Q & A		
		1015	END OF SESSION		

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALLS 23-25

SCIENTIFIC PROGRAM – MONDAY 20 MAY 2019

1100-1230	HAIR AND NAILS Room: Goldfields Theatre Chairs: Prof. R. Sinclair, A/Prof. A. Howard, Dr L. Yip	1100-1230	CONTACT DERMATITIS Room: Eureka Meeting Rooms 2 & 3 Chairs: A/Prof. R. Nixon, Dr A. Lee	1100-1230	FREE PAPERS MEDICAL AND SURGICAL Room: Eureka Meeting Room 1 Chairs: Dr D. Gan, Dr M. Cicchiello
1100-1110	Dr S. Gunatheesan Onycholysis	1100-1130	Dr J. McFadden The role of 'microhistory' and 'microexamination' in the clinical evaluation of contact dermatitis	1100-1115	Dr P. Artemi Systematic treatment of vitiligo. Why, when and how?
1110-1120	A/Prof. J. Kern Onychopapilloma			1115-1130	Dr S. Vaidya Melasma: Use of tranexamic acid-oral, topical, intradermal injections. What's on the horizon?
1120-1130	Dr M. Seith Late onset malalignment of the toenails and clinical pearls from the nail clinic	1130-1140	Dr B. Ricciardo Allergic contact dermatitis to Dermabond Prineo following elective orthopaedic surgery: Case series	1130-1145	Dr D. Dyall-Smith Swabs and pre-existing vulval dermatoses
1130-1145	Prof. R. Sinclair Treatment of alopecia areata: An expert consensus	1140-1205	Dr A. Lee The top ten allergens from the SCF in Victoria in 2018	1145-1200	Dr J. Green It's not just about hair disease
1145-1200	Dr S. Eisman JAK inhibition in the treatment of alopecia areata: The new dawn	1205-1215	Dr N. Amerasinghe Isobornyl acrylate and the rising incidence of reactions to glucose sensors	1200-1215	Prof. N. Haass Optimising melanoma immune checkpoint therapy by pre-treatment with bortezomib (Velcade)
1200-1215	Prof. A. Messenger Frontal fibrosing alopecia pathogenesis and treatment update	1215-1225	A/Prof. R. Nixon Update on prosthetic joint allergy and testing	1215-1230	Dr N. Todes-Taylor Physician burnout
1215-1230	Dr L. Yip Controversies surrounding finasteride treatment for androgenetic alopecia	1225-1230	Discussion	1230	END OF SESSION
1230	END OF SESSION	1230	END OF SESSION		

1230-1330 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1330-1500	MANAGEMENT OF MELANOMA Room: Goldfields Theatre Chairs: A/Prof. C. McCormack, A/Prof. V. Mar, Dr Y. Pan	1330-1500	GENITAL DERMATOLOGY AND HIDRADENITIS SUPPURATIVA Room: Eureka Meeting Rooms 2 & 3 Chairs: Dr E. Veysey, Dr H. Saunders, A/Prof. A. Hall	1330-1500	THE CHALLENGING CONSULTATION Room: Eureka Meeting Room 1 Chairs: Dr J. Yeatman, A/Prof. J. Kern
1330-1350	Dr D. Gyorki What's in a node?	1330-1345	A/Prof. G. Fischer Diagnosis and management of vulvovaginal lichen planus: A retrospective study of 548 patients	1330-1340	Dr P. Bekhor Neurogenic Rosacea
1350-1410	Dr A. Haydon Adjuvant therapies for melanoma in 2019			1340-1400	Prof. G. Littlejohn Central somatisation
1410-1420	A/Prof. V. Mar Mutations, metastasis and surveillance	1345-1405	Dr T. Day Candidiasis, what you need to know	1400-1420	M. Botros Dealing with the difficult patient in the outpatient setting
1420-1500	Prof. J. Bolognia, Prof. C. McLean, Dr D. Gyorki, Dr A. Haydon & A/Prof. V. Mar Panel Discussion: multidisciplinary case discussion	1405-1425	Dr E. McMeniman Updates and recent research on HS	1420-1440	Cl. A/Prof. K. Gebauer Delusional parasitosis
1500	END OF SESSION	1425-1445	Dr A. Hall Male genital dermatology	1440-1500	Dr J. Yeatman An approach to obesity for the Dermatologist
		1445-1500	Q & A	1500	END OF SESSION
		1500	END OF SESSION		

1500-1530 AFTERNOON TEA IN THE TRADE EXHIBITION, HALLS 23-25

ASM 52 SCIENTIFIC PROGRAM – MONDAY 20 MAY 2019

1530-1700	ANNUAL GENERAL MEETING Room: Goldfields Theatre	1530-1700	REGISTRAR TRAINING Room: Eureka Meeting Rooms 2 & 3 Chairs: A/Prof. A. Chong, Dr M. Mohamed
1700	END OF SESSION	1530-1550	A/Prof. C. Schmults Tips to flawless primary closures
		1550-1610	Dr J. McFadden Contact Dermatitis case reports from St John's
		1610-1630	Prof. E. Schmidt Practical tips for the management of autoimmune blistering diseases
		1630-1650	Prof. P. Vabres TBC
		1650-1700	Q & A
		1700	END OF SESSION

1700-1800 MEET THE BOARD, HALLS 23-25

SOCIAL PROGRAM



- 1200 GOLF TOURNAMENT**
Monday 20 May 2019
Arrive at 1200. Tee off at 1230
Royal Melbourne Golf Club, Cheltenham Rd, Black Rock, VIC
- 1800-2000 MEN'S AND LADIES TENNIS TOURNAMENT**
Monday 20 May 2019
Boroondara Tennis Club, Bulleen Rd, Balwyn North, VIC
Please meet at the ASM registration desk at 17:30 sharp
- 1800-1900 TRIVIA NIGHT**
Monday 20 May 2019
Eureka Meeting Room 1
Register your interest at the ASM Registration Desk

Vbeam® Prima

Technology you trust
Innovation you need

Launching on
Saturday 18 May 2019
at ACD ASM



Vbeam Prima now with dual wavelength, dual cooling and more user-friendly features

Vbeam Prima – with new features that benefit both you, and your patient's experience

Vbeam Prima is a highly efficient pulsed-dye laser (PDL) used to treat a variety of indications for both face and body, including benign vascular and pigmented lesions as well as skin rejuvenation and wrinkle reduction.

Everything you love about Vbeam Perfecta but even better...

- Larger 15mm spot size and 50% greater power at 12J with 595 nm
- Patented cryogen-based DCD and EverCool contact cooling
- Calibration on first use
- 1064 nm wavelength
- Smart dye life management

For more information visit
candelamedical.com

CANDELA™
Science. Results. Trust.

TUESDAY 21 MAY 2019

0800-1530 REGISTRATION DESK OPEN

0845-1015	THE DERMATOLOGY PANEL Room: Goldfields Theatre Chairs: Dr M. Mohamed, A/Prof. A. Mar, Dr A. Yazdabadi	0845-1015	HOT TOPICS IN DERMATOLOGY 2019 Room: Eureka Meeting Rooms 2 & 3 Chairs: Dr A. Chamberlain	0845-1015	LYMPHOPROLIFERATIVE DISORDERS Room: Eureka Meeting Room 1 Chairs: A/Prof. C. McCormack, Dr F. Bhabha
0845-1015	Not to be missed! Featuring: Dr Ian McCrossin, Dr James Muir, Prof. Gillian Marshman, Prof. Kurt Gebauer and Dr Belinda Welsh Our experienced panel tackle a range of challenging issues in day to day clinical practice. Topics include frontal fibrosing alopecia, erosive pustular dermatosis on a sun-damaged scalp, the "lost" isotretinoin script, difficult viral warts, pruritus ani, the genitally hyper-vigilant male and what an AI led future may look like.	0845-0905	Dr S. Hannam What's new in the journals part 1	0845-0900	Dr K. Newland CD 30 Lymphoproliferative disease
		0905-0925	Dr A. Chamberlain What's new in the journals part 2	0900-0930	Prof. M. Prince Advances in Cutaneous Lymphoma management
		0925-0930	Q & A	0930-0950	Dr D. A. Khuong Quang Subcutaneous Panniculitis-like TCL
		0930-0942	Prof. S. Kossard Atypical naevus of the elderly and melanoma - a 25 year perspective	0950-1015	Dr C. Vander Weyden, Prof. M. Prince, Dr J. Wells, Dr B. Campbell, Dr S. Lade Case Discussion
		0942-0954	A/Prof. S. Zagarella Evidence based medicine series	1015	END OF SESSION
		0954-1006	Dr J. Cargnello The hair clinic - what have we learned after 28 years?		
1015	END OF SESSION	1006-1015	Q & A		
		1015	END OF SESSION		

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALLS 23-25

1100-1255 ADVANCES IN DERMATOLOGY AND AWARDING OF PRIZES Room: Goldfields Theatre Chairs: A/Prof. R. Nixon, Dr M. Mohamed, Dr A. Yazdabadi, Dr D. Francis

1100-1125	Prof. E. Schmidt Pathogenesis of autoimmune blistering skin disease (including role of genome, microbiome etc)
1125-1150	Prof. P. Vabres Dermoscopy and confocal microscopy in childhood: melanocytic naevi and beyond
1150-1215	A/Prof. C. Schmults Squamous cell cancer, management from in situ to metastasis
1215-1245	Prof. J. Bolognia The many faces of lupus
1245-1255	Awarding of Prizes
1255	END OF SESSION

1255-1355 LUNCH IN THE TRADE EXHIBITION, HALLS 23-25

1355-1515 MEDICARE Q & A Room: Goldfields Theatre Chairs: Dr A. Miller

The Q&A-style session hosted by Dr Andrew Miller will focus on recent schedule changes and other issues relating to Medicare, including the MBS Review. Fellows are encouraged to attend to seek clarification and contribute to discussion on the changing Medicare landscape.

1515 END OF SESSION